amyotrophic lateral sclerosis
Conditions
Interventions
scopolamine patch 7days-washout 7days-placebo patch 7days
placebo patch 7days-washout 7days-scopolamine patch 7days
Sponsors
Mie University Graduate school of medicine,Department of neurology
Matsusaka Chuou Hospital National Mie Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.ALS patients with drooling who were diagnosed by EI Escorial revised Airlie House criteria as clinically definite,clinically probable or clinically pssible ALS. 2.The patients who consented to commit to this research in writing after sufficient informed consent
Exclusion criteria
Exclusion criteria: 1.diagnosed as progressive case delta FS is over 0.67 2.diagnosed as severe hypoventilation and the patient doesn't want to use NIPPV 3.diagnosed as glaucoma 4.diagnosed as benign prostatic hypertrophy 5.past history of intestinal obstruction 6.allergy to this drug 7.pregnant or expecting to be pregnant 8.judged as an inadequate patient by responsible doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of transdermal scopolamine for ALS patients' drooling assessed by VAS(visual analogue scale) and SSS(sialorrhea scoring scale). | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy of transdermal scopolamine for ALS patients' drooling assessed by other scales besides VAS and SSS. Influences on the swallowing dysfunction worthning. Adverse ivents. | — |
Countries
Japan
Contacts
Public ContactYugo Narita
Mie University graduate school of medicine Department of neurology
Outcome results
None listed